IP Library Granted Patent US 8,853,230
Granted Patent B2
US 8,853,230 · App. 13/717,569 · Granted Oct 7, 2014

Inhibitors of JAK

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,230
App. No.
13/717,569
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

Claims (82)

1. A method for inhibiting JAK or a signal transduction pathway mediated at least in part by JAK activity comprising the step of contacting a cell with a compound having the formula I:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

Y 1 is N or CR 1c ;

R 1a is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkenyl, C 2-8 alkynyl, amino, hydroxy, halogen, C 1-8 heteroalkyl, cyano, C 3-8 cycloalkyl, aryl, haloaryl, C 1-8 alkylaryl, and C 1-8 alkoxyaryl, heteroaryl, C 3-8 heterocyclyl and C 3-8 heterocyclylcarbonyl ;

R 1b is H or C 1-8 alkyl;

R 1c is H, C 1-8 alkyl or halogen;

R 2 is H, C 1-8 alkyl, C 1-8 heteroalkyl, heterocyclylC 1-8 alkoxy, halogen or heterocyclyl;

R 3 is H or C 1-8 alkyl or C 3-8 cycloalkyl;

R 4 is selected from the group consisting amino, C 1-8 alkyl, aminoC 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 heteroalkyl, C 3-8 cycloalkyl, aryl, heteroaryl and C 3-8 heterocyclyl; and

m is 0,1,2 or 3.

2. The method of claim 1 wherein said JAK is selected from the group consisting of JAK1, JAK2, and JAK3.

3. The method of claim 1 , wherein said JAK is JAK1 or JAK3.

4. The method of claim 1 , wherein said JAK is JAK3.

5. A method for treating a condition or disorder mediated at least in part by JAK activity selected from the group consisting of organ transplants, asthma, COPD, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Crohn's disease, Type I diabetes and psoriasis in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a a compound having the formula I:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

Y 1 is N or CR 1c ;

R 1a is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkenyl, C 2-8 alkynyl, amino, hydroxy, halogen, C 1-8 heteroalkyl, cyano, C 3-8 cycloalkyl, aryl, haloaryl, C 1-8 alkylaryl, and C 1-8 alkoxyaryl, heteroaryl, C 3-8 heterocyclyl and C 3-8 heterocyclylcarbonyl;

R 1b is H or C 1-8 alkyl;

R 1c is H, C 1-8 alkyl or halogen;

R 2 is H, C 1-8 alkyl, C 1-8 heteroalkyl, heterocyclylC 1-8 alkoxy, halogen or heterocyclyl;

R 3 is H or C 1-8 alkyl or C 3-8 cycloalkyl;

R 4 is selected from the group consisting amino, C 1-8 alkyl, aminoC 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 heteroalkyl, C 3-8 cycloalkyl, aryl, heteroaryl and C 3-8 heterocyclyl; and

m is 0, 1,2 or 3.

6. The method of claim 5 wherein the compound has the formula I:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

Y 1 is N or CR 1c ;

R 1a is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkenyl, C 2-8 alkynyl, amino, hydroxy, halogen, C 1-8 heteroalkyl, cyano, C 3-8 cycloalkyl, aryl, haloaryl, C 1-8 alkylaryl, C 1-8 alkoxyaryl, heteroaryl, C 3-8 heterocyclyl and C 3-8 heterocyclylcarbonyl;

R 1b is H or C 1-8 alkyl;

R 1c is H, C 1-8 alkyl or halogen;

R 2 is H, C 1-8 alkyl, C 1-8 alkoxy or halogen;

R 3 is H or C 1-8 alkyl;

R 4 is selected from the group consisting amino, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 heteroalkyl, C 3-8 cycloalkyl, aryl, heteroaryl and C 3-8 heterocyclyl; and

m is 0, 1, 2 or 3.

7. The method of claim 5 wherein the compound has the formula Ia:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 1a is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkenyl, C 2-8 alkynyl, amino, hydroxy, halogen, C 1-8 heteroalkyl, cyano, C 3-8 cycloalkyl, aryl, haloaryl, C 1-8 alkylaryl, C 1-8 alkoxyaryl, heteroaryl, C 3-8 heterocyclyl and C 3-8 heterocyclylcarbonyl;

R 1b is H or C 1-8 alkyl;

R 2 is H, C 1-8 alkyl, C 1-8 alkoxy or halogen;

R 3 is H or C 1-8 alkyl;

R 4 is selected from the group consisting C 1-8 alkyl, C 1-8 heteroalkyl, C 3-8 cycloalkyl, and amino; and

m is 0, 1,2 or 3.

8. The method of claim 5 wherein the compound has the formula (Ib):

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 1 is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkynyl, hydroxy, halogen, C 1-8 alkoxy, cyano, aminocarbonyl, C 3-8 cycloalkyl, aryl, haloaryl, C 1-8 alkylaryl, C 1-8 alkoxyaryl, heteroaryl, and heterocyclyl, heterocyclylcarbonyl;

R 2a is H, C 1-8 alkyl, C 1-8 alkoxy or halogen;

R 2b is H, C 1-8 alkyl, C 1-8 alkoxy or halogen; and

R 4 is selected from the group consisting C 1-8 alkyl, C 1-8 alkoxyC 1-8 alkylene, C 3-8 cycloalkyl, C 1-8 alkoxy, and amino.

9. The method of claim 5 wherein the compound has the formula (Ic):

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

Y 2 is —CH or —CH—CH—;

R 5 is H, C 1-8 alkyl or hydroxyC 1-8 alkylene; and

R 6 is benzyl, optionally substituted with from 1 to 3 substituents selected from the group consisting of C 2-8 alkynyl, hydroxy, halogen, C 1-8 alkoxy, cyano, aminocarbonyl, C 3-8 cyclopropyl, aryl, haloaryl, C 1-8 alkylaryl, C 1-8 alkoxyaryl, heteroaryl, heterocyclyl and heterocyclylcarbonyl.

10. The method of claim 5 wherein the compound has the formula (Id):

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 5 is C 1-8 alkyl or hydroxyC 1-8 alkylene; or may be taken together with R 8 to form a cyclic ring;

R 7 is C 1-8 alkyl, hydroxy or C 1-8 alkoxy;

R 8 is selected from the group consisting of C 1-8 alkyl, halogen and C 1-8 alkoxy, or may be taken together to form a heterocyclic ring; and

p is 0, 1, 2, or 3 ; and q is 0, 1, 2 or 3.

11. The method of claim 5 wherein the compound has formula (Ie):

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 5 is C 1-8 alkyl or hydroxyC 1-8 alkylene; or may be taken together with R 8a or R 8b to form a cyclic ring;

R 8a is H, halogen, or may be taken together with R 5 to form 5-6 membered carbocyclic ring;

R 8b is H, halogen or, or may be taken together with R 8a to form a heterocyclic ring;

R 8c is H, C 1-8 alkyl, halogen or C 1-8 alkoxy, or may be taken together with R 8b to form a heterocyclic ring;

R 8d is H; and

R 8e is H, halogen or may be taken together with R 5 to form 5-6 membered carbocyclic ring.

12. The method of claim 5 wherein the compound has formula (Ii):

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 5 is H or C 1-8 alkyl;

R 4 is C 1-8 alkyl or heterocyclyl.

13. The method of claim 5 wherein the compound is selected from the group consisting of:

Methyl 3-(5-carbamoyl-4-(2,2,2-trifluoroethylamino)pyrimidin-2-ylamino)phenylcarbamate; 2-(3-(cyclopropanecarboxamido)phenylamino)-4-(2,2,2-trifluoroethylamino)pyrimidine-5-carboxamide; 2-(3-(2-methoxyacetamido)phenylamino)-4-(2,2,2-trifluoroethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2,2,2-trifluoroethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(methylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(ethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(prop-2-ynylamino)pyrimidine-5-carboxamide; 2-(3 -acetamidophenylamino)-4-(isopropylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(cyclopropylmethylamino)pyrimidine-5-carboxamide; 2-(3 -acetamidophenylamino)-4-(tert-butylamino)pyrimidine-5 -carboxamide; 2-(3-acetamidophenylamino)-4-(2-methoxyethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(cyclopentylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(3-methoxypropylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-benzylamino)pyrimidine-5-carboxamide; methyl 5-(5-carbamoyl-4-(2,2,2-trifluoroethylamino)pyrimidin-2-ylamino)-2-chlorophenylcarbamate; 4-(cyclopentylamino)-2-(3-(cyclopropanecarboxamido)phenylamino)pyrimidine-5-carboxamide; 2-(3-(cyclobutanecarboxamido)phenylamino)-4-(cyclopentylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-propionamidophenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; methyl 3-(5-carbamoyl-4-(cyclopentylamino)pyrimidin-2-ylamino)phenylcarbamate; ethyl 3-(5-carbamoyl-4-(cyclopentylamino)pyrimidin-2-ylamino)phenylcarbamate; methyl 5-(5-carbamoyl-4-(cyclopentylamino)pyrimidin-2-ylamino)-2-chlorophenylcarbamate; 4-(benzylamino)-2-(3-(cyclopropanecarboxamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3 -(cyclobutanecarboxamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-propionamidophenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; methyl 3-(4-(benzylamino)-5-carbamoylpyrimidin-2-ylamino)phenylcarbamate; ethyl 3-(4-(benzylamino)-5-carbamoylpyrimidin-2-ylamino)phenylcarbamate; methyl 5-(4-(benzylamino)-5-carbamoylpyrimidin-2-ylamino)-2-chlorophenylcarbamate; 4-(cyclopentylamino)-2-(3-ureidophenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3 -(3-methylureido)phenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(3,3-dimethylureido)phenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(3-ethylureido)phenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(pyrrolidine-1-carboxamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-ureidophenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(3-methylureido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(pyrrolidine-1-carboxamido)phenylamino)pyrimidine-5-carboxamide; isopropyl 3-(4-(benzylamino)-5-carbamoylpyrimidin-2-ylamino)phenylcarbamate; (S)-2-(3-(2-methoxyacetamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-(2-methoxyacetamido)phenylamino)-4-(4-methylbenzylamino)pyrimidine-5-carboxamide ; 2-(3-(2-methoxyacetamido)phenylamino)-4-(4-methoxybenzylamino)pyrimidine-5-carboxamide; 4-(4-chlorobenzylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(3,4-dichlorobenzylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; (R)-2-(3-(2-methoxyacetamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino )-4-(2-hydroxy-2-phenylethylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(2-hydroxy-2-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-amino-2-oxoethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-phenylcyclopropylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(cyclohexylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-((trans)-2-hydroxycyclopentylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(benzyl(methyl)amino)pyrimidine-5-carboxamide; 4-(cyclobutylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(cyclobutylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(phenethylamino)pyrimidine-5-carboxamide; 4-(isopropylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; 2-(3-(2-methoxyacetamido)phenylamino)-4-(2,3,6-trifluorobenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2,3,6-trifluorobenzylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(2-phenylpropylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(1-hydroxy-3-(1H-imidazol-5-yl)propan-2-ylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(3-amino-3-oxopropylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(1-hydroxy-4-methylpentan-2-ylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-(pyrrolidin-1-yl)ethylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-oxo-2-(pyrrolidin-1-yl)ethylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(piperidin-3-ylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(4-methylbenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(4-methoxybenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(4-chlorobenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(3,4-dichlorobenzylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-(methylamino)-2-oxoethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-((2S,3S)-1-hydroxy-3-methylpentan-2-ylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(cyanomethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(tetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(1-hydroxy-3-phenylpropan-2-ylamino)pyrimidine-5-carboxamide; 4-(isopropylamino)-2-(3-(N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-morpholinoethylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(2-phenylpropylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(2-hydroxypropylamino)pyrimidine-5-carboxamide; (R)-2-(3 -acetamidophenylamino)-4-(2,3-dihydroxypropylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-methoxy-2-phenylethylamino)pyrimidine-5-carboxamide; (S)-2-(3 -acetamidophenylamino)-4-(1 -amino-1 -oxopropan-2-ylamino)pyrimidine-5-carboxamide; (R)-2-(3-(2-methoxy-N-methylacetamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; (R)-2-(3-(N-methylacetamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; 4-(isopropylamino)-2-(3-(2-methoxy-N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(cyclopentylamino)-2-(3-(2-methoxy-N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(2-methoxy-N-methylacetamido)phenylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(1-amino-1-oxopropan-2-ylamino)pyrimidine-5 -carboxamide; 2-(3-acetamidophenylamino)-4-(2,3-dihydro-1H-inden-2-ylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(2-hydroxy-1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(3-fluorobenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2,3-difluorobenzylamino)pyrimidine-5-carboxamide; (S)-2-(3-acetamidophenylamino)-4-(2,3-dihydro-1H-inden-1-ylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(2,3-dihydro-1H-inden-1-ylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamidophenylamino)-4-(2-hydroxy-1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(benzo[d][1,3]dioxol -5-ylmethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2-fluorobenzylamino)pyrimidine-5-carboxamide; 2-(3 -acetamidophenylamino)-4-(3-chlorobenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(2,5-difluorobenzylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(4-fluorobenzylamino)pyrimidine-5-carboxamide; 4-(4-fluorobenzylamino)-2-(3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; and (R)-4-(1-phenylethylamino)-2-(3-(pyrrolidine-1-carboxamido)phenylamino)pyrimidine-5-carboxamide; 2-(3-acetamido-4-chlorophenylamino)-4-(benzylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(4-chloro-3-(2-methoxyacetamido)phenylamino)pyrimidine-5-carboxamide; 4-(benzylamino)-2-(4-chloro-3-(3-cyclobutylureido)phenylamino)pyrimidine-5-carboxamide; (R)-2-(3-acetamido-4-chlorophenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; (R)-2-(4-chloro-3-(2-methoxyacetamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; (R)-2-(4-chloro-3-(cyclopropanecarboxamido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; (R)-2-(4-chloro-3-(3-cyclobutylureido)phenylamino)-4-(1-phenylethylamino)pyrimidine-5-carboxamide; 2-(3-acetamidophenylamino)-4-(benzylamino)-N-methylpyrimidine-5-carboxamide; 4-(benzylamino)-2-(3-(2-methoxyacetamido)phenylamino)-N-methylpyrimidine-5-carboxamide ; methoxyacetamido)phenylamino)-N-methylpyrimidine-5-carboxamide; benzyl 3-((2-(3-acetamidophenylamino)-5-carbamoylpyrimidin-4-ylamino)methyl)piperidine-1-carboxylate; and 6-(3-acetamidophenylamino)-4-(benzylamino)nicotinamide.

14. The method of claim 5 wherein the compound is 2-(4-chloro-3-(pyrrolidine-1-carboxamido)phenylamino)-4-(2-fluorobenzylamino)pyrimidine-5 -carboxamide or a pharmaceutically acceptable salt thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054975/0203 →
CHANGE OF NAME Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054976/0294 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2014
From: BAUER, SHAWN M.; ROSE, JACK W.; SONG, YONGHONG; XU, QING; MEHROTRA, MUKUND; HUANG, WOLIN; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 033531/0053 →